| Finding | What the evidence says | Planning use |
|---|---|---|
| Night shift work with circadian disruption | IARC classified it as a probable human carcinogen (Group 2A) in 2007, on limited human evidence and sufficient evidence in experimental animals. | Treat it as a reason to protect sleep and light timing. It is not proof of cause in any individual worker. |
| Low natural melatonin | Low natural levels are associated with a higher risk of developing cancer. | An association only. It does not show that a pill reverses the risk. |
| Melatonin alongside conventional therapy | Cancer Choices reports strong evidence of longer survival and higher remission rates in solid-tumor cancers, and modest evidence of fewer side effects. It reports insufficient evidence of a survival effect in advanced cancer. | Raise it with the oncology team before starting. It is a complementary option. |
| Supplement to offset circadian disruption | It has not been shown that a supplement alone counteracts the risks of circadian rhythm disruption. | Light and schedule habits still matter. |
| Typical adult supplement dose | 1 to 5 mg daily, while many clinical studies used unusually high doses. | Do not copy trial doses from headlines. |
Figures come from the IARC classification as summarised in an EPA HERO record of the IARC evaluation and from the Cancer Choices melatonin review.
The link between melatonin and cancer rests on several lines of evidence: lab studies, night shift work data and treatment trials. Whether supplements prevent cancer remains undetermined, and any use alongside therapy belongs with an oncology team.
For the wider context on diet, supplements and risk, see our overview of natural health and cancer prevention research.
Night shift work and cancer risk
The International Agency for Research on Cancer (IARC) classified “shift work that involves circadian disruption” as a probable human carcinogen, Group 2A, in 2007, according to the published evaluation record. The classification rested on limited human evidence and sufficient evidence in experimental animals. That mix signals a hazard worth managing. It does not predict an outcome for any single worker.
Observational work on breast cancer points the same way. Breastcancer.org notes that in some studies women with lower melatonin levels, such as those who work the night shift or sleep fewer hours, may have a higher breast cancer risk. The IARC working group also flagged a weakness in the human studies. The definition of “shift work” varies from study to study, so results are hard to compare.
The working group named the domains that future studies should capture: shift system, years on the schedule and shift intensity. These points change how you should read night shift findings.
- Check the exposure being described. A study that lumps all non-day work together says little about a specific rota or career length.
- Separate the classification from the risk. Group 2A reflects the strength of the evidence, not the size of risk for an individual.
- Keep the melatonin link in proportion. Lower melatonin among night workers is an observed pattern in some studies, not a demonstrated mechanism that supplements can fix.
Light at night and melatonin levels
Darkness cues the body to produce melatonin. Cancer Choices describes shift work and bright lights in the evening as disruptions to the circadian rhythm that may lower natural melatonin. It adds that avoiding them may help raise natural levels.
The practical consequence is that timing and lighting deserve as much attention as any pill. Night workers cannot always avoid disruption, so the useful question is which parts of the routine can be adjusted.
- Evening light: bright light in the evening is one of the disruptions named alongside shift work, so it is a sensible place to start for anyone who can control their environment.
- Shift work: where the schedule cannot change, the same source suggests that the disruption itself, not just melatonin supply, is what carries the concern.
- Supplements as a fix: it has not been shown that a melatonin supplement alone offsets the risks of circadian disruption, so a tablet should not be treated as a licence to ignore sleep and light habits.
Melatonin alongside cancer treatment
Adjuvant therapy means a treatment added to the main treatment. Cancer Choices reviews melatonin in that role and reports strong evidence that melatonin taken alongside conventional therapy may improve survival and remission rates in solid-tumor cancers. It also reports modest evidence of fewer side effects overall. For advanced cancer, it finds insufficient evidence of any effect on survival.
Those findings support a cautious conversation with an oncology team, not a do-it-yourself plan. The benefit appears tied to use alongside standard care, and the evidence differs by cancer stage.
Supplement doses versus trial doses
Over-the-counter use and research use differ sharply. Cancer Choices gives a typical adult dose of 1 to 5 mg daily, and Breastcancer.org mentions a suggested range of 0.5 to 5 mg per day. Cancer Choices also notes that many of the clinical studies it reviewed used unusually high doses, up to 40 mg nightly, and that more research is needed on the right doses in cancer treatment.
The decision rule that follows is simple. Do not take a trial dose as a target because a study reported results. Dose questions belong with the care team, especially during treatment.
Safety and long-term use
Breastcancer.org states that short-term use of melatonin appears safe, but the risks of long-term use are not fully understood. That is a reason for caution with open-ended use, particularly when it is chosen for cancer reasons rather than sleep.
- High-dose effects: some users have reported headaches, drowsiness, confusion, nightmares and trouble sleeping at high doses.
- Hormone questions: a single case study in 2008 suggested that one woman had higher estradiol levels during melatonin therapy. One report cannot establish a pattern, but it is a reason to mention melatonin to a clinician managing hormone-sensitive cancer.
- Start low: the lower end of the ranges quoted above is the sensible reference point for anyone considering supplements without supervision.
Lab findings and the circadian mechanism
In the lab, melatonin appears to slow the growth of breast cancer cells, according to Breastcancer.org. This is the tumor-suppression evidence that draws most interest. The same source stresses that whether melatonin supplements can help prevent or treat breast cancer is yet to be determined and that much more research is needed.
The circadian angle gives the lab findings context. IARC’s classification of shift work leaned on sufficient evidence in experimental animals, and low natural melatonin is associated with higher cancer risk. Those findings point to the body’s day-night cycle as a plausible link, though they do not prove that restoring melatonin with a pill breaks the chain.
Related reading on prevention
Melatonin is one of many supplements discussed in cancer research. If you are weighing others, our guide on do antioxidants prevent cancer covers a different group of compounds. For food-based approaches, see foods that may help prevent cancer.
Frequently asked questions
Can melatonin replace conventional cancer treatment?
No. Cancer Choices describes melatonin as a complementary therapy used alongside standard medical care, not a standalone treatment for cancer.
Which medicines and conditions call for extra care with melatonin?
Breastcancer.org says melatonin may interact with blood thinners and with medicines for diabetes and seizures. Cancer Choices adds that some studies suggest it can worsen autoimmune diseases. Check with a pharmacist or doctor first if any of these apply.
What is melatonin?
Melatonin is a hormone the body naturally produces as part of the circadian rhythm, the daily sleep-wake cycle. Darkness cues its release, which is why light at night is relevant to the research.
